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1.1. Introduction
Atherosclerotic cardiovascular disease (CVD) remains the
major cause of premature death in Europe, even though
CVD mortality has fallen considerably over recent decades in
many European countries.
Over three-quarters of all CVD mortality may be prevented
by adequate lifestyle modiﬁcations.
1.2. Evaluation methods
The present guidelines follow the quality criteria for develop-
ment of guidelines (www.escardio.org/knowledge/guidelines/
rules).
The level of evidence and the strength of recommendation
of particular treatment options are presented in Tables 1 and 2.
Speciﬁc quality indicators and the GRADE rating system are
presented in Table 3.Table 1 – Classes of recommendations.
Classes of 
recommendations
Definitio n
a lareneg ro/dna ecnedivE I ssalC
that a given t reatment or 
is beneficial, use ful, e ffect 
Class II  Conflicting evidence  and/
divergence o f opinion  abo
usefulness/efficacy o f the 
treatment or p rocedure. 
    Class IIa Weight o f evidence/opini
favour o f usefulness/effica 
    Class IIb Usefulness/efficacy is less 
established  by evidence/o
Class III Evidence or gene ral agree
the given t reatment or p r
is not use ful/e ffective,  and
cases may be h arm ful. 2. Why is prevention of cardiovascular disease
needed?
Key messages
 Atherosclerotic CVD, especially chronic heart disease
(CHD), remains the leading cause of premature death
worldwide.
 CVD affects both men and women; of all deaths before the
age of 75 years in Europe, 42% are due to CVD in women and
38% in men.
 CVD mortality is changing with declining age-standardized
rates in most European countries, remaining high in Eastern
Europe.
 Prevention works: >50% of the reductions in CHD mortality
relate to changes in risk factors, and 40% to improved
treatments (Fig. 1).
 Preventive efforts should be lifelong, from birth (if not
before) to old age.Suggested  wording to use
 tnemeerg
 procedu re 
ive. 
Is recommended/is 
indicated
or a 
ut the 
given 
on is in 
cy. 
Should be considered
 well 
pinion. 
May be conside red
ment that 
ocedu re 
 in some 
Is not  recommended
Table 3 – Quality of evidence used in GRADE.
Study limitations Non-concealment of allocation ; non-blinding of 
outcome assessment; high losses to foll ow-up ; 
no intention-to-t reat ana lysis.
Inconsistent 
findings
Variability due to dif ferences in patients 
studied, intervention, outcomes assessed.
Indirectness o f 
evidence 
Head-to-head comparisons a re di rect ; 
intervention A vs. control and B vs . control is 
indirect in assessing  A vs . B.
Imprecision Small patient numbers  resulting in wide 
confidence intervals.
Publication bias Typically trials sh owing no ef fect of 
intervention are not published or a re 
published in local non-inde xed journals.
Table 2 – Levels of evidence.
Level of 
evidence A 
Data derived from multiple randomized 
clinical trials or meta-analyses. 
Level of 
evidence B 
Data derived from a single randomized 
clinical trial or large non-randomized 
studies. 
Level of 
evidence C 
Consensus of opinion of the experts and/
or small studies, retrospective studies, 
registries.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9e172 Population and high-risk preventive strategies should be
complementary; an approach limited to high-risk persons
will be less effective; population education programmes are
still needed.
 Despite gaps in our understanding, there is ample evidence
to justify intensive public health and individual preventive
efforts.
 There is still substantial room for improvement in risk factor
control, even in individuals at very high risk.
3. Who should beneﬁt from it?
3.1. Strategies and risk estimation
Key messages
 In apparently healthy persons, CVD risk is most frequently
the result of multiple interacting risk factors.
 A risk estimation system such as SCORE (Systematic
COronary Risk Evaluation) can assist in making logical
management decisions, and may help to avoid both under-
and overtreatment.United States, '68–'76
New Zealand, '74–'81
The Netherlands, '78–'85
United States, '80–'90
Finland, '72–'92
IMPACT New Zealand, '82–'93
IMPACT Scotland, '75–'94
IMPACT England & Wales, '81–'00
IMPACT Italy, '80–'00
IMPACT United States, '80–'00
IMPACT Finland, '82–'97
IMPACT Sweden, '86–'02
40
40
46
43
24
35
35
38
40
47
23
36
0%
Fig. 1 – Percentage of the decrease in deaths from coronary hear
different populations. Adapted from Di Chiara et al. Certain individuals are at high CVD risk without needing risk
scoring and require immediate intervention for all risk
factors.
 In younger persons, a low absolute risk may conceal a very
high relative risk, and use of the relative risk chart or
calculation of their 'risk age' may help in advising for
intensive lifestyle changes.
 While women appear to be at lower CVD risk than men, this
is misleading as risk is deferred by 10 years rather than
avoided.
 All risk estimation systems are relatively crude and require
attention to qualiﬁers.
 Additional factors affecting risk can be accommodated in
electronic risk estimation systems such as HeartScore
(www.heartscore.org).
 The total risk approach allows ﬂexibility: if perfection cannot
be achieved with one risk factor, risk can still be reduced by
trying harder with others.Treatments Risk factors Unexplained
50% 100%
54
60
44
50
76
60
55
52
55
44
53
55
6
10
7
5
10
10
5
9
24
9
t disease attributed to treatments and risk factor changes in
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9 e173Recommendations regarding risk estimation.
Recommendation s Classa Levelb GRADE
Total risk estimation using 
multiple risk factors (such as 
SCORE) is  recommended  for 
asymptomatic adults without 
evidence of CV D.
I C St rong
High-risk individuals can be 
detected on the basis of 
established CVD, diabetes
mellitus , moderate to
severe  renal diseas e, very
high levels of individual risk
factors, or a high SCORE risk,
and are a high priority for
intensive advice about all risk
factors.        
I C St rong
CVD = cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
3.1.1. Risk estimation
Persons with established CVD are already at very high risk of
further events and need prompt intervention on all risk
factors, while in apparently healthy persons total risk should
be assessed using the SCORE system.
Risk factor screening including the lipid proﬁle should be
considered in the following situations:
 The person asks for it.
 Men 40 years, and women 50, or if postmenopausal.
 One or more risk factors such as smoking, overweight,
hyperlipidaemia, hypertension or diabetes are known.
 A family history of premature CVD or major risk factors such
as hyperlipidaemia or diabetes.
 Symptoms suggestive of CVD.
Special efforts should be made to assess risk in the socially
deprived, who are more likely to carry a heavy burden of risk
factors.
Risk charts such as SCORE are intended to facilitate risk
estimation in apparently healthy persons.
In the Czech Republic, we use a calibrated country-speciﬁc
SCORE chart based on the mortality data provided by the
Institute of Health Information and Statistics of the Czech
Republic, and risk factor prevalence from the Czech MONICA
(Multinational MONItoring of trends and determinants in
CArdiovascular disease) and the Czech post-MONICA studies;
it is available in 2 versions: for total cholesterol and the total/
HDL-cholesterol ratio (Figs. 2 and 3).
A particular problem relates to young people with high
levels of risk factors: a low absolute risk may conceal a high
relative risk requiring advice for intensive lifestyle measures.
A new approach to this problem in these guidelines is
cardiovascular risk age (Fig. 4). It is not currently recom-
mended to base treatment decisions on risk age.
In some age categories, the majority, especially of men, will
have estimated cardiovascular death risk exceeding 5–10%
based on age (and gender) only, even when other cardiovas-cular risk factor levels are relatively low. This could lead to
excessive use of drugs in the elderly.
The role of high-density lipoprotein (HDL) cholesterol in
risk estimation has been systematically re-examined using the
SCORE database. HDL cholesterol can contribute substantially
to risk estimation if entered as an independent variable, it
modiﬁes risk at all levels of risk as estimated from the SCORE
cholesterol charts. This effect is seen in both sexes and in all
age groups, including older women. This is particularly
important at levels of risk just below the threshold for
intensive risk modiﬁcation of 5%. Many of these subjects will
qualify for intensive advice if their HDL cholesterol is low. The
electronic, interactive version of SCORE—Heart Score (available
at www.heartscore.org)—is currently being adapted to allow
adjustment for the impact of HDL cholesterol on total risk.
The fasting triglyceride effect is attenuated by adjustment
for other factors, especially HDL cholesterol. Non-fasting
triglycerides may be more strongly related to risk indepen-
dently of the effects of HDL cholesterol.
Heart rate is an independent risk factor for CVD in
the general population. Sudden cardiac death was particu-
larly associated with elevated resting heart rate. Measure-
ment of resting heart rate should be done in the sitting
position after 5 min rest and should be part of the routine
physical examination when assessing cardiovascular risk.
No trial of heart rate lowering for CVD prevention in a
healthy population has been conducted to date; therefore,
pharmacological lowering of heart rate in primary prevention
cannot be currently recommended.
Elevated heart rate is associated with increased risk of further
cardiac events in those with established CVD. In post-myocar-
dial infarction (MI) and in heart failure patients, use of beta-
blockers at carefully titrated doses is associated with improved
outcomes. More recently, in patients with resting heart rates
70 b.p.m. and reduced left ventricular function, trials of pure
heart reduction have shown beneﬁt. There is currently not
enough evidence to recommend a target heart rate.
The impact of diabetes on risk appears greater than in the
Framingham cohort, with relative risks of 5 in women and 3
in men.
How to use the risk estimation charts
 To estimate a person's 10-year risk of CVD death, ﬁnd the
correct table for their gender, smoking status, and age.
Within the table ﬁnd the cell nearest to the person's BP and
total cholesterol or total/HDL-cholesterol ratio. Risk esti-
mates will need to be adjusted upwards as the person
approaches the next age category.
 Low-risk persons should be offered advice to maintain their
low-risk status. Individuals at risk of CVD death of 5%
qualify for intensive advice, and may beneﬁt from drug
treatment. At risk levels >10%, drug treatment is more
frequently required. In persons older than 60, these thresh-
olds should be interpreted more leniently, because their
age-speciﬁc risk is normally around these levels, even when
other cardiovascular risk factor levels are ‘‘normal’’.
Qualiﬁer
 At any given age, risk estimates are lower for women than
for men. The risk is merely deferred in women, with a
Fig. 2 – 10-year risk of fatal cardiovascular disease for the Czech population based on the following risk factors: age, sex,
smoking, systolic blood pressure and total cholesterol.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9e17460-year-old woman resembling a 50-year-old man in terms
of risk.
Risk may also be higher than indicated in the charts in:
 Sedentary subjects and those with central obesity;
overweight individuals (risk is greater in younger sub-
jects).
 Socially deprived individuals and ethnic minorities.
 Individuals with diabetes: SCORE charts should be only used
in those with type 1 diabetes without target organ damage.
Risk rises with increasing blood sugar concentration before
overt diabetes occurs.
 Individuals with low HDL cholesterol, increased triglycer-
ides, ﬁbrinogen, apolipoprotein B (apoB), and lipoprotein(a)
[Lp(a)] levels, especially in combination with familial
hypercholesterolaemia, and perhaps increased high-sensi-
tivity C-reactive protein (hsCRP). In particular, a low HDL
level will indicate a higher level of risk in both sexes, all age
groups, and at all levels of risk. Asymptomatic individuals with preclinical evidence of
atherosclerosis (e.g., plaque on carotid ultrasonography).
 Those with moderate to severe chronic kidney disease (CKD)
[glomerular ﬁltration rate (GFR) < 60 mL/min/1.73 m2].
 Positive family history of premature CVD.
Priorities
The higher the risk, the greater the beneﬁt from preventive
efforts:
1. Very high risk
 Documented CVD by invasive or non-invasive testing,
previous MI, acute coronary syndrome (ACS), coronary
revascularization [percutaneous coronary intervention
(PCI), coronary artery bypass grafting (CABG)], and other
revascularization procedures, ischaemic stroke, periph-
eral arterial disease (PAD).
 Diabetes mellitus (type 1 or type 2) with one or more
cardiovascular risk factors and/or target organ damage
(e.g., microalbuminuria: 30–300 mg/24 h).
Fig. 3 – 10-year risk of fatal cardiovascular disease for the Czech population based on the following risk factors: age, sex, smoking,
systolic blood pressure and total/HDL cholesterol ratio.
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 A calculated SCORE 10%.
2. High risk
 Markedly elevated single risk factors such as familial
dyslipidaemias and severe hypertension.
 Diabetes mellitus (type 1 or type 2) but without cardio-
vascular risk factors or target organ damage.
 Moderate CKD (GFR 30–59 mL/min/1.73 m2).
 A calculated SCORE of 5% and <10% for 10-year risk of
fatal CVD.
3. Moderate risk
Subjects with their SCORE 1 and <5% at 10 years. This
risk is further modulated by factors mentioned above.
4. Low risk
The low-risk category applies to individuals with a SCORE
<1% and free of qualiﬁers that would put them at moderate
risk.3.2. Genetics
Familial prevalence of atherosclerotic disease or major risk
factors (high BP, diabetes mellitus, hyperlipidaemia) should be
systematically sought for in the ﬁrst-degree relatives of any
patient affected before 55 years in men and 65 years in women.
Family history is a variable combination of genetics and shared
environment.
3.3. Age and gender
CVD is the major cause of death in women in all European
countries; below 75 years, 42% of women die from CVD
compared with 38% of men. The lower rates of CHD in
women—but not of stroke—may be interpreted as a protective
effect of endogenous estrogens. Sex differences in dietary fat
intake (rather than excess smoking in men) may also be
responsible. CVD mortality does not accelerate after the
Fig. 4 – Illustration of the risk-age concept.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9e176menopause indicting that women postpone their risk rather
than avoiding it altogether.
3.4. Psychosocial risk factors
Key messages
 Low socio-economic status, lack of social support, stress
at work and in family life, depression, anxiety, hostility,
and type D personality contribute to the risk of developing
CVD and worsening of the clinical course and prognosis of
CVD.3.5. Other biomarkers of risk
Key messages
 Novel biomarkers have limited additional value when added
to CVD risk assessment with the SCORE algorithm.
Two groups of systemic biomarkers relevant to CVD risk
assessment were identiﬁed:
 Inﬂammatory: hsCRP, ﬁbrinogen.
 Thrombotic: homocysteine, lipoprotein-associated phos-
pholipase A2 (LpPLA2).
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Recommendation s Classa Levelb GRADE
High-sensitivity CRP may be 
measu red as pa rt of refined 
risk assessment in patients 
with an unusual or moderate 
CVD risk p rofil e.
IIb B Weak
High-sensitivity CRP 
should not be measured 
in asymptomatic low-risk 
individuals and high-risk 
patients to assess 10-year risk 
of CVD.
III B St rong
Fibrinogen may be measu red 
as part of refined risk 
assessment in patients with 
an unusual or moderate CVD 
risk profil e.
IIb B Weak
Fibrinogen should not be 
measu red in asymptomatic 
low-risk individuals and
 high-risk patients to assess 
10-year risk of CV D.
III B St rong
CRP = C-reactive protein; CVD = cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
Recommendations for thrombotic biomarkers.
Recommendation s Classa Levelb GRADE
Homocysteine may be 
measu red as pa rt of a  refined 
risk assessment in patients 
with an unusual or moderate 
CVD risk p rofil e.
IIb B Weak
Homocysteine should not be 
measu red to monitor CVD 
risk prevention.
III B St rong
LpPLA2 may be measu red 
as part of a  refined risk 
assessment in patients at 
high risk of a recurrent acute 
atheroth rombotic  event.
IIb B Weak
CVD = cardiovascular disease; LpPLA2 = lipoprotein-associated phos-
pholipase.
aClass of recommendation.
bLevel of evidence.3.6. Imaging methods in cardiovascular disease
prevention
Key message
 Imaging methods can be relevant in CVD risk assessment in
moderate-risk individuals.
Recommendations regarding imaging methods.
Recommendation s Classa Levelb GRADE
Measurement of ca rotid 
intima-media thickness and/or 
screening  for athe roscle rotic 
plaques by ca rotid arte ry 
scanning should be 
conside red  for ca rdi ovascular 
risk assessment in 
asymptomatic adults at 
moderate risk.
IIa B St rong
Measurement of ankle–
brachial index should be 
conside red  for ca rdi ovascular 
risk assessment in 
asymptomatic adults at 
moderate risk . 
IIa B St rong
Computed tomogr aphy  for 
corona ry calcium should be 
conside red  for ca rdi ovascular 
risk assessment in 
asymptomatic adults at 
moderate risk.
IIa B Weak
Exercise elect roca rdiogr aphy 
may be conside red 
for ca rdi ovascular risk 
assessment in moderate-
risk asymptomatic adults 
(including sedentary 
adults considering sta rting 
a vigorous e xercise 
programme) , particular ly 
when attention is paid to 
non-electrocardiogram 
markers such as exercise 
capacit y.
IIb B St rong
aClass of recommendation.
bLevel of evidence.
3.7. Other diseases with increased risk for cardiovascular
disease
Several diseases with infection or non-infectious inﬂammato-
ry processes are associated with an increased cardiovascular
event rate.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9e178Recommendations regarding other diseases with in-
creased risk for cardiovascular disease.
Recommendation s Classa Levelb GRADE
In patients with chronic 
kidney diseas e, risk factors 
have to be attended to in the 
same way as  for  very high-
risk persons. 
I C St rong
All persons with obstructive 
sleep apnoea should under go 
medical assessment , including 
risk stratification and risk 
management.
IIa A St rong
All men with erectile 
dysfunction should under go 
medical assessment , including 
risk stratification and risk 
management.
IIa B St rong
aClass of recommendation.
bLevel of evidence.
3.7.1. Inﬂuenza
Inﬂuenza epidemics are associated with an increased rate of
cardiovascular events. Inﬂuenza vaccination as a population-
wide prevention measure was associated with a very cost-
effective reduction in clinical events. Annual inﬂuenza vaccina-
tions are recommended for patients with established CVD.
3.7.2. Chronic kidney disease
Inﬂammatory mediators and promoters of calciﬁcation are
increased and inhibitors of calciﬁcation are reduced in CKD.
Microalbuminuria increases cardiovascular risk two- to four-
fold. A decreasing GFR is an indicator of increased risk for CVD
and all-cause mortality.
Lipid lowering appears useful in a wide range of patients
with advanced CKD but with no known history of MI or
coronary revascularization.
3.7.3. Obstructive sleep apnoea
Obstructive sleep apnoea (OSA) is associated with increased
cardiovascular morbidity and mortality. Treating OSA in
patients with chronic coronary artery disease and hyperten-
sion may decrease cardiac events and cardiac death.
3.7.4. Erectile dysfunction
Erectile dysfunction (ED) has a high prevalence in individuals with
multiple cardiovascular risk factors and in individuals with CVD.
3.7.5. Autoimmune diseases
3.7.5.1. Psoriasis. Psoriasis is an independent risk factor for
MI. The risk of MI associated with psoriasis is greatest in young
patients with severe psoriasis, is attenuated with age, and
remains increased even after controlling for traditional
cardiovascular risk factors.
3.7.5.2. Rheumatoid arthritis. Patients with rheumatoid ar-
thritis are twice as likely as the general population to suffer an
MI;theyalsohavehighermortalitypost-MI.CVDriskis increased
at an early stage of the disease, and this risk excess is possibly
related to systemic inﬂammation and a prothrombotic state.3.7.5.3. Lupus erythematosus. Systemic lupus erythematosus
is associated with endothelial dysfunction and an increased
risk of CHD.
3.7.6. Periodontitis
Periodontitis is associated with endothelial dysfunction,
atherosclerosis, and an increased risk of MI and stroke.
Confounding factors, however, such as low socio-economic
status and cigarette smoking, probably play a signiﬁcant role.
3.7.7. Vascular disease after radiation exposure
The incidence of ischaemic heart disease and stroke is
increased many years after radiation exposure for treatment
of lymphomas and for breast cancer as well as for head and
neck cancer. Patients after radiation exposure should make
every effort to optimize their risk factor proﬁle.
3.7.8. Vascular disease after transplantation
Cardiac allograft vasculopathy is the leading cause of late
morbidity and mortality in heart transplant patients. Statins
improve endothelial dysfunction, slows the development of
cardiac allograft vasculopathy, and beneﬁts survival.
4. How can cardiovascular disease prevention
be used?
4.1. Principles of behaviour change
Key message
 Cognitive-behavioural methods are effective in supporting
persons in adopting a healthy lifestyle.
Recommendations for behavioural change.
Recommendation s Classa Levelb GRADE
Established cognitive-
behavioural strategies ( e.g . 
motivational inte rvi ewing) to 
facilitate li festyle change a re 
recommended.
I A St rong
Specialized healthcare 
professionals ( e.g . nurses , 
dieticians, psychologists, etc.) 
should be invol ved when ever 
necessary and  feasibl e.
IIa A St rong
In individuals at very high 
CVD risk , multimodal 
interventions , integrating 
education on healt hy lifestyle 
and medical resou rces, 
exercise training , stress 
management, and counselling 
on psychosocial risk factors, 
are  recommended.
I A St rong
CVD = cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
• Saturated fatty acids to account  for <10% of total ener gy inta ke, 
 th rough  replacement  by polyunsaturated fatty acids.
• Trans-unsaturated fatty acids : as little as possible, preferably no inta ke 
  from processed  food, and <1% of total ener gy inta ke f rom natural 
 origin.
• <5 g of salt per d ay.
• 30–45 g of fib re per day, from wholegrain p roducts , fruits, 
 and  vegetables.
• 200 g of fruit per d ay (2–3 se rvings).
• 200 g of  vegetables per d ay (2–3 se rvings).
• Fish at least twice a  week , one of which to be oi ly fish.
• Consumption of alcoholic b everages should be limited to t wo glasses 
 per d ay (20 g/d ay of alcohol)  for men and one glass per day
 (10 g/d ay of alcohol)  for  women.
Table 4 – Principles of effective communication to
facilitate behavioural change.
• Spend enough time with the individual to c reate a ther apeutic 
  relationship— even a  few more mi nutes can ma ke a dif ferenc e.
• Acknowledge the individual ’s personal vi ew of his/her disease and 
  contributing factors.
• Encourage exp ression of  worries and anxieties , concerns, and
 self- evaluation of motivation  for beh aviour change and chances of 
 success.
• Speak to the individual in his/her  own language and be suppo rti ve of 
  every imp rovement in li festyl e.
• Ask questions to check that the individual has understood the advice 
  and has any suppo rt th ey  requi re to  foll ow it.
• Acknowledge that changing li fe-long habits can be difficult and that 
  gradual change that is sustained is often mo re permanent than a 
  rapid chang e.
• Accept that individuals m ay need suppo rt  for a long time and that 
  repeated ef forts to encourage and maintain li festyle change m ay be 
 necessa ry in ma ny individuals.
• Ma ke su re that all health p rofessionals i nvol ved p rovide consistent 
 in formation.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9 e179Use of the following principles of communication will
facilitate treatment and prevention of CVD (Table 4).
4.2. Smoking
Key messages
 Changing smoking behaviour is a cornerstone of improved
CVD health.
 Public health measures including smoking bans are crucial
for the public's perception of smoking as an important
health hazard.
Recommendations regarding smoking.
Recommendation s Classa Levelb GRADE
All smoking is a strong and 
independent risk factor for 
CVD and has to be  avoided.
I B St rong
Exposure to passi ve smoking 
increases risk of CVD and has 
to be  avoided.
I B St rong
Young people h ave to be 
encouraged not to take up 
smoking.
I C St rong
All smokers should be gi ven 
advice to quit and be of fered 
assistance.
I A St rong
CVD = cardiovascular disease.
aClass of recommendation.
bLevel of evidence.
4.2.1. Introduction
Smoking is associated with increased risk of all types of CVD.
According to estimations from SCORE, 10-year fatal cardiovas-cular risk is approximately doubled in smokers. However,
while the relative risk of MI in smokers >60 years of age is
doubled, the relative risk in smokers <50 years is ﬁve times
higher than in non-smokers.
4.2.2. Dosage and type
The risk associated with smoking is primarily related to the
amount of tobacco smoked daily and shows a clear dose–respon-
se relationship with no lower limit for deleterious effects. Dura-
tion also plays a role; all types of smoked tobacco are harmful.
4.2.3. Passive smoking
Passive smoking increases the risk of CHD. A non-smoker
living with a smoking spouse has an estimated 30% higher
risk, and exposure in the workplace is associated with a similar
risk increment. Recently imposed public smoking bans in
different geographic locations have led to a signiﬁcant
decrease in the incidence of MI.
4.2.4. Smoking cessation
Stopping smoking after a MI is potentially the most effective of
all preventive measures. The risk is rapidly reduced after
cessation, with signiﬁcant morbidity reductions reported
within the ﬁrst 6 months.
Quitting must be encouraged in all smokers (Table 5).
Smoking cessation therapies
Quitting smoking is a difﬁcult process because the habit is
strongly addictive.
Pharmacological aid consistently improves quit rates. An
advice, nicotine replacement therapy, varenicline or bupro-
pion should be offered to assist cessation.
4.3. Nutrition
Key messages
 A healthy diet has the following characteristics: Energy intake should be limited to the amount of energy
needed to maintain (or obtain) a healthy weight, i.e., a body
mass index (BMI) < 25 kg/m2.
 In general, when following the rules for a healthy diet, no
dietary supplements are needed.
Table 5 – The 'Five As' for a smoking cessation strategy for
routine practice.
A–SK:
Systematically inqui re about  smoking  status  at 
every oppo rtunit y.
A–ADVISE : Unequivocal ly urge  all  smo kers  to  quit .
A–ASSESS:
Determine the  person ’s deg ree  of  addiction  and 
readiness to qui t
A–ASSIST:
Agree  on  a smoking  cessation  strate gy, including 
setting a quit dat e, behavioural counselling , and 
pharmacological support.
A–ARRANGE: Arrange a  schedule of  foll ow-u p.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9e1804.4. Physical activity
Key message
 Participation in regular physical activity is associated with a
decrease in cardiovascular mortality.
Recommendations regarding physical activity.Recommendation s Classa Levelb GRADE
Healthy adults of all ages 
should spend 2.5–5 h a 
week on physical activity or 
aerobic e xercise training of 
at least moderate intensity, 
or 1–2.5 h a  week on 
vigorous intense e xercis e. 
Sedenta ry subjects should 
be strong ly encouraged to 
start light-intensity e xercise 
programmes.
I A St rong
Physical activity/ae robic 
exercise training should be 
performed in  multiple bouts 
each lasting ≥10 min and 
even ly sp read th roughout the 
week, i.e. on 4–5 days a  week.
IIa A St rong
Patients with previous acute 
myoca rdial infa rction , CABG, 
PCI, stable angina pectoris, or 
stable chronic hea rt failu re 
should undergo moderate-
to-vigorous intensity ae robic 
exercise training  ≥3 times a 
week and 30 min per session . 
Sedenta ry patients should 
be strong ly encouraged to 
start light-intensity e xercise 
I A St rongCABG = coronary artery bypass graft; PCI = percutaneous coronary
intervention.
aClass of recommendation.
bLevel of evidence.
programmes after adequate 
exercise- related risk 
stratification.4.5. Management of psychosocial factors
Key message
 Psychological interventions can counteract psychosocial
stress and promote healthy behaviours and lifestyle.
Recommendations on the management of psychosocial
factors.
Recommendation s Classa Levelb GRADE
Multimodal behavioural 
interventions , integrating 
health education, physical 
exercis e, and psychological 
therapy  for psychosocial 
risk factors and coping with 
illness, should be prescribed.
I A St rong
In the case of clinically 
significant symptoms of 
depression , anxiety, and 
hostility, psychotherapy, 
medication , or collaborati ve 
care should be conside red . 
This app roach can reduce 
mood symptoms and enhance 
health-related quality of 
life, although  evidence  for 
a definite beneficial effect 
on cardiac endpoints is 
inconclusive. 
IIa A St rong
aClass of recommendation.
bLevel of evidence.
4.6. Body weight
Key messages
 Both overweight and obesity are associated with a risk of
death from CVD.
 There is a positive linear association of BMI with all-cause
mortality.
 All-cause mortality is lowest with BMI of 20–25 kg/m2.
 Further weight reduction cannot be considered protective
against CVD.
The health effects of increasing body weight are summa-
rized in Table 6.
4.7. Blood pressure
Key message
 Elevated BP is a major risk factor for CHD, heart failure,
cerebrovascular disease, PAD, renal failure, and atrial
ﬁbrillation.
Recommendations on blood pressure.
Recommendations Classa Levelb GRADE
Lifestyle measu res such as weight cont rol , increased physical activit y, alcohol moderation, sodium restriction , and 
increased consumption of fruits, vegetables , and low-fat dai ry p roducts a re  recommended in all patients with 
hypertension and in individuals with high normal B P.
I B St rong
All major antihypertensi ve drug classes (i. e. diuretics, ACE inhibitors, calcium antagonists , angiotensin receptor 
antagonists, and beta-bloc kers) do not dif fer significantly in their BP-l owering efficacy and thus should be 
recommended  for the initiation and maintenance of anti hypertensive t reatment.
I A St rong
Beta-blockers and thiazide diuretics a re not  recommended in  hypertensi ve patients with  multiple metabolic risk 
factors increasing the risk of n ew-onset diabetes . 
III A St rong
In patients with diabetes , an ACE inhibitor or a  renin–angiotensin  receptor blocker is  recommended. I A St rong
Risk stratification using the SCORE risk cha rt is recommended as a minimal  requi rement in each  hypertensive 
patient.
I B St rong
However, as there is evidence that subclinical organ damage p redicts ca rdi ovascular death independent ly of 
SCORE, a search for subclinical organ damage should be encouraged , particular ly in individuals at l ow or moderate 
risk (SCORE 1–4%).
IIa B Weak
Drug treatment is  recommended to be initiated p romptly in patients with grade 3  hypertension , as well as in 
patients with grade 1 or 2  hypertension who are at high or  very high total cardi ovascular risk . 
I C St rong
In patients with grade 1 or 2  hypertension and at moderate total cardi ovascular risk, drug treatment m ay be 
delayed  for s everal weeks , and in grade 1 hypertensive patients without a ny other risk facto r, for several months 
while trying lifestyle measu res.
IIb C Weak
Systolic BP should be lowered to <140 mmHg (and diastolic BP <90 mmHg) in all  hypertensi ve patients. IIa A St rong
All hypertensi ve patients with established ca rdi ovascular diseas e, or with type 2 diabetes, or with an estimated
10-year risk of ca rdi ovascular death  ≥5% (based on the SCORE cha rt) should be conside red  for statin ther apy. IIa B St rong
Antiplatelet ther apy, in particular l ow-dose aspirin , is recommended  for hypertensive patients with ca rdi ovascular 
events. 
I A St rong
Antiplatelet ther apy m ay be conside red in  hypertensi ve patients without a histo ry of ca rdi ovascular diseas e, but 
with reduced  renal function or at high ca rdi ovascular risk.
IIb A Weak
ACE inhibitor = angiotensin-converting enzyme inhibitor; BP = blood pressure.
aClass of recommendation.
bLevel of evidence.
Table 6 – Potential adverse cardiovascular effects of
increasing body weight.
• Inc reases in insulin  resistance (glucose intoleranc e, type 2 diabetes 
  mellitus).
• Inc reased blood p ressu re.
• Inc reased systemic inflammation and p rothrombotic stat e.
• Albumi nuria.
• Dyslipidaemia (el evated total choleste rol , LDL cholesterol , non-HDL 
 choleste rol , trig lycerides , apolipop rotein B , small dense LDL particles , 
  decreased HDL choleste rol , apolipop rotein  A1).
• Ca rdi ovascular and ce reb rovascular abnormalities (endothelial 
  dysfunction , heart failu re, corona ry hea rt diseas e, atrial fibrillation, 
 st roke, abnormal left ventricular geomet ry, systolic and diastolic 
 dysfunction, increased sympathetic activity).
HDL = high-density lipoprotein; LDL = low-density lipoprotein.
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The deﬁnition and classiﬁcation of hypertension are shown in
Table 7.
4.7.2. Blood pressure measurement
Blood pressure should be measured in each individual several
times, on several separate occasions.
4.7.3. Ofﬁce or clinic blood pressure measurement
Non-mercury BP measuring devices are becoming increasingly
important. These devices should be properly tested and
validated according to standardized protocols. The ausculta-
tory technique with a trained observer and a mercury
sphygmomanometer continues to be the method of choice
for measurement.
4.7.4. Ambulatory and home blood pressure monitoring
Ambulatory and home BP values are closely related to
prognosis. They allow to diagnose ‘‘white coat’’ or isolated
Table 8 – Blood pressure thresholds for definition of
hypertension with different types of blood pressure
measurement.
SBP (mmHg) DBP (mmHg)
Office or clinic 140 90
24-hour 125 –130 80
Day 130–135 85
Night 120 70
Home 130–135 85
BP = blood pressure; DPB = diastolic blood pressure; SBP = systolic
blood pressure.
Table 7 – Definitions and classification of blood pressure
levels.a
Category Systolic BP 
(mmHg)
Diastolic BP 
(mmHg)
Optimal <12 0 an d <80
Normal 120–12 9 and/o r 80–84
High normal 130–13 9 and/o r 85–89
Grade 1 hype rtensio n 140–15 9 and/o r 90–99
Grade 2 hype rtensio n 160–17 9 and/o r 100–109
Grade 3 hype rtension ≥180 and/or ≥110
Isolated systolic 
hype rtension 
≥140 an d <90
BP = blood pressure.
aBP levels in untreated individuals.
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normal ambulatory BP values), and ‘‘masked’’ hypertension
(characterized by normal ofﬁce BP with high ambulatory
BP values). BP thresholds for the deﬁnition of hypertension by
24-h ambulatory and home BP monitoring differ from those
measured at ofﬁce or clinic (Table 8).
Diagnosis and treatment of hypertension are still largely
based on ofﬁce or clinic BP.
4.7.5. Risk stratiﬁcation in hypertension
Evaluation of history, physical and laboratory examination
should identify the:
 presence of clinically established cardiovascular or renal
disease
 presence of subclinical CVD
 co-existence of other cardiovascular risk factors.
Risk stratiﬁcation using the SCORE risk chart is a minimal
requirement in each hypertensive patient. Factors inﬂuencing
prognosis in hypertension are summarized in Table 9.Subclinical organ damage predicts cardiovascular death
independently of SCORE, and the combination may improve
risk prediction, especially in subjects at low or moderate risk
(SCORE 1–4%).
4.7.6. Whom to treat and when to initiate antihypertensive
treatment
The decision to start antihypertensive treatment depends on
BP (Table 7) and total cardiovascular risk (Table 9). All patients
in whom repeated BP measurements show grade 2 or 3
hypertension are candidates for treatment as BP reduction
lowers cardiovascular morbidity and mortality independently
of their level of total risk.
Drug treatment should be initiated promptly in grade 3
hypertension, as well as in patients with grade 1 and 2
hypertension who are at high or very high total cardiovascular
risk. In patients with grade 1 or 2 hypertension at moderate
total cardiovascular risk, drug treatment may be delayed for
several weeks, and for several months in those with grade 1
hypertension without any other risk factor.
In patients with diabetes and high-normal BP, initiation of
drug treatment may only be recommended if subclinical organ
damage (particularly microalbuminuria or proteinuria) is
present.
Lifestyle measures and close BP monitoring should be
recommended for individuals with high normal BP who are at
low or moderate added risk.
4.7.7. How to treat
4.7.7.1. Lifestyle. Lifestyle interventions alone may be sufﬁ-
cient for patients with mildly elevated BP; in treated
individuals, they may reduce the dosage of antihypertensive
medication.
Lifestyle interventions include weight reduction in over-
weight individuals; reduction in the use of sodium chloride to
<5 g/day; restriction of alcohol consumption to no more than
20 g/day ethanol in men and to no more than 10 g/day ethanol
in women; and regular physical activity.
Hypertensive patients should eat more fruits and vegeta-
bles (4–6 servings per day each, i.e., 400 g each) and reduce
intake of saturated fat and cholesterol.
4.7.7.2. Antihypertensive drugs. (a) The main beneﬁts of
antihypertensive treatment are due to lowering of BP per se,
and are largely independent of the drugs employed; (b)
thiazide and thiazide-like diuretics (chlorthalidone and inda-
pamide), beta-blockers, calcium antagonists, angiotensin-
converting enzyme (ACE) inhibitors, and angiotensin receptor
blockers (ARBs) can adequately lower BP, and signiﬁcantly
reduce risk of cardiovascular morbidity and mortality. These
drugs are thus all recommended for initiation and mainte-
nance of antihypertensive treatment, either as monotherapy
or in combination.
Beta-blockers are slightly inferior in preventing stroke but
have an effect similar to other antihypertensive agents in
preventing coronary events and heart failure, and higher efﬁcacy
than other drugs in patients with a recent coronary event.
As beta-blockers induce weight gain, have adverse effects
on lipid metabolism, and increase (compared with other drugs)
the incidence of new-onset diabetes, they should not be
Table 9 – Factors influencing prognosis in hypertension.
Risk factor Target o rgan d amage Di abetes mellitu s Est ablished CVD or  renal disease
SBP and DBP Elect roca rdiogr aphic  LVH 
(Sokol ow– Lyons >38 mm or 
Cornell >2440 mm/ms); or 
Novacode  LVMI >130 g/m2 (M), 
>115 g/m2 (F).
Fasting plasma glucose 
≥7.0 mmol/L (126 mg/dL)
or post-load plasma 
glucose 
>11.0 mmol/L (198 mg/dL).
Cereb rovascular disease : ischaemic stroke, 
cerebral haemo rrhag e, transient ischaemic 
attack.
Pulse pressu re (in the elderly) Echoca rdiographic LVHa 
[LVMI  ≥125 g/m2 (M), 
≥110 g/m2 (F)]
Heart disease : myocardial infa rction , angina, 
corona ry  revascularization , heart failu re. 
Age (M >55 years , F >65 years) Ca rotid wall thic kening 
(IMT >0.9 mm) or plaque 
Renal disease: diabetic nephropat hy, renal 
impairment [serum creatinine >133 µmol/L 
(1.5 mg/dL) (M), >124 µmol/L (1.4 mg/dL) 
(F)], protei nuria (>300 mg/24 h).
Smoking Carotid– femoral PWV >12 m/s PAD
Dyslipidaemia : TC >5.0 mmol/L (190 mg/dL) ; 
or LDL choleste rol >3.0 mmol/L (115 mg/dL) ; 
or HDL choleste rol <1.0 mmol/L (40 mg/dL) 
(M), <1.2 mmol/L (46 mg/dL) (F); 
or TG >1.7 mmol/L (150 mg/dL)
ABI <0.9 Advanced retinopat hy: haemorrhages or 
exudates, papilloedema.
Fasting plasma glucose 
5.5–6.9 mmol/L (100–125 mg/dL)
Slight inc rease in plasma 
creatinine : 115–133 µmol/L 
(1.3–1.5 mg/dL) (M) , 107–124 
µmol/L (1.2–1.4 mg/dL) (F)
Abnormal glucose tolerance test Low eGFRb (<60  mL/min/1.73  m2) 
or creatinine  clearanc ec (<60  mL /
min)
Abdominal obesity: waist circum ference 
>102 cm (M), >88 cm (F)
Microalbumi nuria 30–300 mg/24 
h or albumin/c reatinine ratio : 
≥22 mg/g ( ≥2.5 mg/mmol)
(M), ≥31 mg/g ( ≥3.5 mg/mmol) (F)
Family histo ry of prematu re CVD : 
age <55 years (M) , <65 years (F).
ABI = ankle–brachial index; CVD = cardiovascular disease; DBP = diastolic blood pressure; eGFR = estimated glomerular ﬁltration rate;
F = females; HDL = high-density lipoprotein; IMT = intima–media thickness; LDL = low-density lipoprotein; LVH = left ventricular hypertrophy;
LVMI = left ventricular mass index; M = males; PAD = peripheral artery disease; PWV = pulse wave velocity; SBP = systolic blood pressure;
TC = total cholesterol; TG = triglycerides.
aRisk maximal for concentric LVH: increased LVMI with a wall thickness/radius ratio I0.42.
bModiﬁcation of Diet in Renal Disease (MDRD) formula.
cCockcroft–Gault formula.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9 e183preferred in hypertensive patients with multiple metabolic
risk factors (i.e. abdominal obesity, impaired fasting glucose,
and impaired glucose tolerance), conditions that increase the
risk of new-onset diabetes. This also applies to thiazide
diuretics, which have dyslipidemic and diabetogenic effects,
particularly when used at high doses. Thiazides have often
been administered together with beta-blockers in trials
showing a relative excess of new-onset diabetes, thus making
a distinction between the contributions of the two agents
difﬁcult to dissociate. This may not apply to vasodilating
beta-blockers such as carvedilol and nebivolol, which have
less or no dysmetabolic action, as well as a reduced
incidence of new-onset diabetes compared with conven-
tional beta-blockers.ACE inhibitors and ARBs are particularly effective in
reducing left ventricular hypertrophy (LVH), including the
ﬁbrotic component; they are also quite effective in reducing
microalbuminuria and proteinuria and in preserving renal
function and delaying end-stage renal disease; calcium
antagonists, besides being effective in LVH, appear particularly
beneﬁcial in slowing down progression of carotid hypertrophy
and atherosclerosis.
Alpha1-blockers, centrally acting agents [alpa2-adrenore-
ceptor agonists and imidazoline (I1) receptor agonists], and
antialdosterone drugs effectively lower BP. However, no data
document the ability of these drugs to reduce cardiovascular
morbidity and mortality in hypertension. Nevertheless, all of
these agents have frequently been used as added drugs in
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9e184trials documenting cardiovascular protection and can thus be
used for combination treatment.
Drugs with 24-h efﬁcacy should be preferred. Simpliﬁcation
of treatment improves adherence to therapy, while effective
24-h BP control is prognostically important in addition to
‘‘ofﬁce’’ BP control. Long-acting drugs also minimize BP
variability.
4.7.7.3. Combination treatment. The extra BP reduction from
combining drugs from two different classes is approximately
ﬁve times greater than doubling the dose of one drug. The
combination of two drugs may also offer advantages for
treatment initiation, particularly in high-risk patients in
whom early BP control may be desirable. Fixed-dose combina-
tions simplify treatment and may thus improve patient
compliance. Trial evidence of outcome reduction has been
obtained particularly for the combination of a diuretic with an
ACE inhibitor or an ARB or calcium antagonist.
Despite trial evidence of outcome reduction, the beta-
blocker/diuretic combination favours the development of
diabetes and should thus be avoided unless required for other
reasons. The combination of an ACE inhibitor and an ARB is
associated with a consistent increase in serious side effects.
In 15–20% of hypertensive patients, a combination of three
drugs is needed to achieve BP control; the most rational
combinations appear to be a blocker of the renin–angiotensin
system, a calcium antagonist, and a diuretic at effective doses.
4.7.7.4. Blood pressure goals. There is sufﬁcient evidence to
recommend SBP lowering to <140 mmHg (and DBP to
<90 mmHg) in all hypertensive patients. Evidence is only
missing in the elderly hypertensive patient, in whom the
beneﬁt of lowering SBP <140 mmHg has not been tested in
randomized trials.
The recommendation of previous guidelines to aim at a
lower SBP goal (<130 mmHg) in patients with diabetes and
those at very high cardiovascular risk (previous cardiovascular
events) is not consistently supported by trial evidence.
Based on current data, it may be prudent to recommend
lowering SBP/DBP to values within the range 130–139/80–
85 mmHg.
4.7.7.5. Hypertension in special conditions. Diabetes mellitus
(see Section 4.8)
In patients with diabetes, antihypertensive treatment
should always be initiated when the BP is 140/90 mmHg.
Initiation of treatment in the high-normal BP range is at present
not sufﬁciently supported by outcome evidence from trials.Combination treatment is commonly needed to lower BP
effectively in diabetes. A renin–angiotensin system blocker
(ACE inhibitor/ARB) should always be included because of the
evidence of its superior protective effect against initiation or
progression of nephropathy.
Hypertension in the elderly
Treatment is highly beneﬁcial in the elderly hypertensive
patient. Thiazide diuretics, ACE inhibitors, calcium antago-
nists, ARBs, and beta-blockers can be considered for initiation
and maintenance of treatment also in the elderly.
Evidence is now available from an outcome trial that
antihypertensive treatment also has beneﬁts in patients
aged 80 years. Treatment with BP-lowering drugs should
be continued or initiated when patients turn 80, starting
with monotherapy and adding a second drug if needed. The
decision to treat should be taken on an individual basis, and
patients should always be carefully monitored during
treatment, with BP also measured in the standing position.
4.7.7.6. Duration of treatment. Generally, antihypertensive
therapy should be maintained indeﬁnitely.
4.7.7.7. Lipid-lowering drugs. All hypertensive patients
with established CVD or with type 2 diabetes or with an
estimated 10-year risk of cardiovascular death 5% (based on
the SCORE chart) should be considered for statin therapy—
Section 4.9.
4.7.7.8. Antiplatelet therapy. Antiplatelet therapy, in particu-
lar low-dose aspirin, should be prescribed to hypertensive
patients with cardiovascular events. It can also be considered
in hypertensive patients without a history of CVD, with
reduced renal function, or at high cardiovascular risk. In
patients receiving aspirin is increased possibility of bleeding,
particularly gastrointestinal.
4.8. Treatment targets in patients with type 2 diabetes
Key messages
 Intensive management of hyperglycaemia in diabetes
reduces the risk of microvascular complications and, to a
lesser extent, that of CVD.
 Intensive treatment of BP in diabetes reduces the risk of
macrovascular and microvascular outcomes.
Recommendations on diabetes mellitus.
Recommendations Classa Levelb GRADE
The target HbA1c  for the p revention of CVD in diabetes of <7.0% (<53 mmol/mol) is recommended . I A St rong
Statins are  recommended to  reduce ca rdi ovascular risk in diabetes. I A St rong
Hypoglycaemia and excessive  weight gain  must be avoided and individual  app roaches (both targets and drug 
choices) may be necessary in patients with complex diseas e.
I B St rong
Metformin should be used as first-line ther apy if tolerated and not contraindicated IIa B St rong
Further reductions in HbA1c to a target of <6.5% (<48 mmol/mol) (the l owest possible sa fely  reached HbA1c) m ay 
be useful at diagnosis . For patients with a long duration of diabetes this target m ay  reduce risk of mic rovascular 
outcomes.
IIb B Weak
BP targets in diabetes are  recommend to be <140/80 mmHg. I A St rong
Target LDL choleste rol is <2.5 mmol/L, for patients without athe roscle rotic disease total choleste rol m ay be 
<4.5 mmol/L, with a lower LDL choleste rol target of <1.8 mmol/L (using higher doses of statins) for diabetic 
patients at very high CVD risk.
IIb B Weak
Antiplatelet ther apy with aspirin is not recommended  for people with diabetes who do not h ave clinical  evidence 
of atherosclerotic disease.
III A St rong
ACS = acute coronary syndrome; BP = blood pressure; CKD = chronic kidney disease; CVD = cardiovascular disease; HbA1c = glycated
haemoglobin; LDL = low-density lipoprotein.
aClass of recommendation.
bLevel of evidence.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9 e1854.8.1. Microalbuminuria and multifactorial intervention.
Microalbuminuria (urinary albumin excretion 30–300 mg/24 h)
predicts the development of overt diabetic nephropathy in
patients with type 1 or type 2 diabetes, while the presence of
overt proteinuria (>300 mg/24 h) generally indicates
established renal parenchymal damage. Microalbuminuria—
even below the current threshold values—predicts
cardiovascular events, and there is a continuous
relationship between cardiovascular as well as
noncardiovascular mortality and urinary protein/creatinine
ratios. Patients with microalbuminuria and proteinuria
should be treated with an ACE inhibitor or an ARB regardless
of baseline BP.
4.9. Lipids
Key messages
 Increased plasma cholesterol and low-density lipoprotein
(LDL) cholesterol are among the main risk factors for CVD.
 Hypertriglyceridaemia and low HDL cholesterol are inde-
pendent CVD risk factors.
 Statin therapy has a beneﬁcial effect on atherosclerotic CVD
outcomes.
4.9.1. Low-density lipoprotein cholesterol
There is a clear dose-dependent relative reduction in CVD with
LDL cholesterol lowering. Every 1.0 mmol/L reduction in LDL
cholesterol is associated with a corresponding 20–25% reduc-
tion in CVD mortality and non-fatal MI.4.9.2. Apolipoprotein B
Apolipoprotein B can substitute LDL cholesterol and provides a
better index of the adequacy of LDL-lowering therapy. If
measured, it should be <80 and <100 mg/dL in subjects at very
high or high CVD risk, respectively.
4.9.3. Triglycerides
Hypertriglyceridaemia is a signiﬁcant independent CVD risk
factor; the association is closer with moderately increased
triglycerides than with very severe hypertriglyceridaemia
(>10 mmol/L), which is associated with high risk for develop-
ing pancreatitis.
At present, fasting triglycerides >1.7 mmol/L continue to be
considered a marker of increased risk, but concentrations
1.7 mmol/L are not evidence-based target levels for therapy.
4.9.4. High-density lipoprotein cholesterol
Low concentrations of HDL cholesterol are independently
associated with higher CVD risk. The combination of moder-
ately elevated triglycerides and low concentrations of HDL
cholesterol is very common in high-risk patients with type 2
diabetes, abdominal obesity, insulin resistance, and physically
inactive. HDL cholesterol <1.0 mmol/L in men and <1.2 mmol/L
in women may be regarded as a marker of increased risk. There
is still not enough evidence for any HDL cholesterol value to be
considered as a goal of therapy.
4.9.5. Lipoprotein(a)
High concentrations of Lp(a) are associated with increased risk
of CHD and ischaemic stroke. There is no justiﬁcation for
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9e186screening in the general population of Lp(a) at present and no
evidence that any value should be considered as a target.
4.9.6. Calculated lipoprotein variables
Low-density lipoprotein cholesterol
Low-density lipoprotein cholesterol is usually calculated
using the Friedewald formula (valid only with triglycerides
levels <4.5 mmol/L).
Non-high-density lipoprotein cholesterol
Non-HDL cholesterol comprises the cholesterol in LDL,
intermediate-density lipoprotein, and VLDL particles. Non-
HDL cholesterol predicts CVD risk similarly to or even better
than LDL cholesterol. LDL limits may be transferred to non-
HDL limits by adding 0.8 mmol/L. Calculation: non-HDL
chol = total chol  HDL chol; does not require the triglyceride
concentration to be <4.5 mmol/L.
4.9.7. Who should be treated and what are the goals?Recommendations on management of hyperlipidaemia.
Recommendations Classa Levelb GRADE
The recommended target l evels are <5 mmol/L (less than ~190 mg/dL)  for total plasma choleste rol and 
<3 mmol/L (less than ~115 mg/dL) for LDL choleste rol for subjects at low or moderate risk.
I A St rong
In patients at high CVD risk , an LDL cholesterol  goal <2.5 mmol/L (less than ~100 mg/dL) is  recommended . I A St rong
In patients at  very high CVD risk , the recommended LDL choleste rol target is <1.8 mmol/L (less than ~70 mg/dL) 
or a ≥50% LDL cholesterol  reduction when the target l evel cannot be  reached. I A St rong
All patients with familial hype rcholesterolaemia  must be  recognized as high-risk patients and be t reated with 
lipid-l owering therapy.
I A St rong
In patients with an  ACS , statin treatment in high doses has to be initiated while the patients a re in hospital. I A St rong
Prevention of non-haemo rrhagic st roke: treatment with statins  must be started in all patients with established 
atheroscle rotic disease and in patients at high risk  for d eveloping CVD. Treatment with statins  must be sta rted 
in patients with a histo ry of non-ca rdioembolic ischaemic st roke. 
I A St rong
Occlusi ve arterial disease of the l ower limbs and ca rotid a rte ry disease a re CHD risk-equivalent conditions and 
lipid-l owering therapy is  recommended.
I A St rong
Statins should be considered as the first-line drugs in transplant patients with dyslipidaemia. IIa B St rong
Chronic kidn ey disease (stages 2–5, i.e. GFR <90 mL/min/1.73 m2) is acknowledged as a CHD risk-equivalent and 
the LDL choleste rol target in these patients should be adapted to the degree of renal failure.
IIa C St rong
ACS = acute coronary syndrome; CHD = coronary heart disease; CVD = cardiovasular disease; GFR = glomerular ﬁltration rate; LDL = low-density
lipoprotein.
aClass of recommendation.
bLevel of evidence.The beneﬁt of cholesterol-lowering therapy depends on initial
levels of risk: the higher the risk, the greater the beneﬁt
(Table 10).
4.9.8. Patients with peripheral arterial disease
Occlusive arterial disease of the lower limbs and carotid
artery disease are CHD risk-equivalent conditions, and lipid-
lowering therapy is recommended in these patients irre-
spective of their plasma lipid levels. However, increasedcarotid intima–media thickness (IMT) without evidence of
atherosclerotic plaques is not an indication for lipid-lowering
treatment in patients without proven CVD or other risk factors.
The beneﬁt of lipid-lowering treatment in abdominal aortic
aneurysm and atherosclerosis in other types of arteries (e.g.
retinal arteries) remains to be proven.
4.9.9. Stroke prevention
High cholesterol levels are a risk factor for ischaemic but not
haemorrhagic stroke. Therefore, patients with ischaemic
cerebrovascular disease merit the same degree of attention
to treatment of plasma lipids as do patients with CHD.
In the prevention of stroke, treatment with statins should be
started in all patients with atherosclerotic disease and in
patients at high risk for developing CVD. After a cerebrovascular
event, statins should be started in patients with a history of non-
cardioembolic ischaemic stroke or transient ischaemic attack,
but should be avoided following haemorrhagic stroke unless
there is evidence of atherosclerotic disease or high CVD risk.4.9.10. Patients with kidney disease
Chronic kidney disease is characterized by mixed dyslipidae-
mia (high triglycerides, high LDL cholesterol, and low HDL
cholesterol). Microalbuminuria is a risk factor for CVD while
CKD is acknowledged as a CHD-risk equivalent.
The statin dose should be modiﬁed according to GFR.
Statin therapy has a beneﬁcial effect on CVD outcomes in
CKD stages 2 and 3 and slows the rate of kidney function
loss.
Table 10 – Intervention strategies as a function of total cardiovascular risk and low-density lipoprotein cholesterol level.
Total CV  risk
(SCORE)
%
LDL-C lvels
<70 mg/dL
<1.8 mmol/L
70 to <100 mg/dL
 1.8 to <2.5 mmol/L
100 to <155 mg/dL
2.5 to <4.0 mmol/L
155 to <190 mg/dL
4.0 to <4.9 mmol/L
>190 mg/dL
>4.9 mmol/L
noitnevretni elytsefiLnoitnevretni elytsefiLnoitnevretni dipil oNnoitnevretni dipil oN1<
Lifestyle inte rvention, 
consider drug if 
uncontrolled
Classa/Levelb I/C I/C I/C I/C IIa/A
≥1 to <5 Li festyle intervention Li festyle inte rvention
Lifestyle inte rvention, 
consider drug if 
uncontrolled
Lifestyle inte rvention, 
consider drug if 
uncontrolled
Lifestyle inte rvention, 
consider drug if 
uncontrolled
Classa/Levelb I/C I/C IIa/A IIa/A I/A
>5 to <10 , or high risk
Lifestyle intervention,
consider drug
Li festyle inte rvention,
consider drug
Lifestyle inte rvention
and immediate drug 
intervention
Lifestyle inte rvention
and immediate drug 
intervention
Lifestyle inte rvention
and immediate drug 
intervention
Classa/Levelb IIa/A IIa/A IIa/A I/A I/A
≥10 or very high risk
Lifestyle intervention,
consider drug*
Lifestyle intervention
and immediate drug 
intervention
Lifestyle inte rvention
and immediate drug 
intervention
Lifestyle inte rvention
and immediate drug 
intervention
Lifestyle inte rvention
and immediate drug 
intervention
Classa/Levelb IIa/A IIa/A I/A I/A I/A
CV = cardiovascular; LDL = low-density lipoprotein.
aClass of recommendation.
bLevel of evidence.
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Dyslipidaemia is common in this patient population, and
pharmacotherapy is required. Statins are recommended as the
ﬁrst-line drugs.
Initiation should be at low doses with careful up-titration
and with caution regarding potential drug-drug interactions,
particularly for those on cyclosporin.
4.9.12. Patients with an acute coronary syndrome
Statin treatment in high doses has to be initiated as early as
possible while the patients are in the hospital, aiming to reach
the LDL cholesterol level of <1.8 mmol/L. The early drug
treatment should be combined with effective lifestyle changes
after hospital discharge.
4.9.13. Drugs
The currently available lipid-lowering drugs include statins,
ﬁbrates, bile acid sequestrants, niacin (nicotinic acid), and
selective cholesterol absorption inhibitors (e.g., ezetimibe).
Statins reduce cardiovascular morbidity and mortality as
well as the need for coronary artery interventions. Statins also
seem to halt progression or even contribute to regression of
coronary atherosclerosis. Therefore, they should be used as
the drugs of ﬁrst choice in the highest tolerable doses in
patients with hypercholesterolaemia or combined hyperlipi-
daemia.
Higher activity of liver enzymes in plasma occurs occa-
sionally, and in most cases is reversible: 5–10% of patients
receiving statins develop myopathy, but rhabdomyolysis is
extremely rare. The risk of myopathy can be minimized by
identifying vulnerable patients and/or by avoiding statin
interactions with speciﬁc drugs (Table 11).There are reports indicating increased blood sugar and
HbA1c levels, i.e., increased risk of type 2 diabetes, as a possible
adverse effect of long-term statin therapy. Nevertheless, the
beneﬁts of statins far outweigh the risk for vast majority of
patients.
Non-statin treatment: selective cholesterol absorption inhi-
bitors are not used as monotherapy to decrease LDL cholesterol
concentrations. Bile acid sequestrants also decrease total and
LDL cholesterol but tend to increase triglyceride concentrations.
Fibrates and niacin are used primarily for triglyceride lowering
and increasing HDL cholesterol, while ﬁsh oils (omega-3 fatty
acids) for triglyceride lowering.
4.9.14. Drug combinations
Statins should be used at the highest tolerable doses before
combination therapy.
Combinations of a statin and a bile acid sequestrant or a
statin and ezetimibe can be used for greater reduction of LDL
cholesterol.
Combinations of niacin and a statin increase HDL choles-
terol and decrease triglycerides, but ﬂushing as the main
adverse effect of niacin may affect compliance.
Fibrates, particularly fenoﬁbrate, may be useful, not only
for decreasing high triglyceride concentrations and increasing
low HDL cholesterol, but can further lower LDL cholesterol
when applied together with a statin. Other drugs metabolized
through cytochrome P450 should be avoided when this
combination is prescribed. Fibrates should preferably be taken
in the morning and statins in the evening to minimize peak
dose concentrations and decrease the risk of myopathy.
Patients have to be instructed about warning symptoms
(myalgia).
Table 11 – Selected drugs that may increase risk of
myopathy and rhabdomyolysis when used concomi-
tantly with statin (CYP3A4 inhibitors/substrates or other
mechanisms).
Cyclosporin , tacroli mus
Macrolides (azith romycin, clarithromycin, eryth romycin)
Azole antifungals (itraconazole, ketoconazol e, fluconazole)
Calcium anta gonists (mibefradil , diltiazem, ver apamil)
Nefazodone
HIV protease inhibitors (amp ren avir, indin avi r, nelfinavi r, ritonavi r, 
saquinavir)
Sildenafil
Others
 Di goxin , niacin, fibrates (particular ly gemfib rozil)
Table 12 – Recommendations for promoting medication
adherence.
• Provide clear advice  rega rding the benefits and possible ad verse 
 ef fects of the medication , and the duration and timing of dosing.
• Consider patients’ habits and p references.
• Reduce dosage demands to the l owest  feasible l evel.
• Ask patients in a non-judgemental w ay h ow the medication  works 
  for them , and discuss possible reasons  for non-adhe rence ( e.g . side 
 ef fects , worries).
• Implement  repetiti ve monitoring and  feedback.
• In the case of lack of tim e, introduce p hysicians assistants and/or 
 trained  nurses when ever its necessa ry and  feasibl e.
• In the case of persistent non-adhe renc e, offer  multisession or 
  combined beh avioural inte rventions.
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Recommendations on antithrombotic therapy with and
without overt CVD are summarized in the following table:Recommendations on antithrombotic therapy.
Recommendations Classa Levelb GRADE
In the acute phase of coronary arte ry synd romes and for the  following 12 months , dual antiplatelet therapy with a 
P2Y12 inhibitor (ticagrelor or prasug rel) a dded to aspirin is  recommended unless contraindicated due to such as 
excessive risk of bleeding . 
I B St rong
Clopidog rel (600 mg loading dos e, 75 mg dai ly dose) is recommended  for patients who cannot  receive ticagrelor 
or prasugrel.
I A St rong
In the chronic phase (>12 months) after  myoca rdial infa rction, aspirin is recommended  for secondary prevention. I A St rong
In patients with non-ca rdioembolic transient ischaemic attack or ischaemic st roke, secondary prevention with 
either dipyridamole plus aspirin or clopidog rel alone is  recommended . 
I A St rong
In the case of intolerance to di pyridamole (headache) or clopidog rel , aspirin alone is  recommended. I A St rong
In patients with non-ca rdioembolic ce rebral ischaemic events, anticoagulation is not superior to aspirin and is not 
recommended.
III B Weak
Aspirin or clopidog rel cannot be  recommended in individuals without ca rdi ovascular or ce reb rovascular disease 
due to the increased risk of major bleeding.
III B Weak
aClass of recommendation.
bLevel of evidence.4.10.1. Antithrombotic therapy in atrial ﬁbrillation
Recommendations for antithrombotic therapy should be
based on the presence (or absence) of risk factors for stroke
and thromboembolism, and we refer further to the recent
guidelines if the Task Force for the management of Atrial
Fibrillation of the European Society of Cardiology.
4.11. Adherence
Key messages
 Adherence to medication in high-risk individuals and in
patients with CVD is still low. Several types of interventions are effective in improving
medication adherence (Table 12).
 Reducing dosage is the most effective single approach to
enhancing medication adherence.
5. Where should programmes be offered?
Key message
 Cardiovascular disease is the single most important cause of
death and can often be prevented!
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 1 6 9 – e 1 8 9 e189Recommendation on nurse-co-ordinated care.
Recommendation s Classa Levelb GRADE
Nurse-co-ordinated 
prevention p rogrammes 
should be well integrated into 
healthcare systems . 
IIa B St rong
aClass of recommendation.
bLevel of evidence.
5.1. Cardiovascular disease prevention in primary care:
role of nurses
Key message
 Nurse-coordinated prevention programmes are effective.
5.2. Cardiovascular disease prevention in general practice
Key messages
 The general practitioner is the key person to initiate,
coordinate, and provide long-term follow-up for CVD
prevention. They have a unique role in identifying individu-
als at risk of but without established CVD and assessing their
eligibility for intervention based on their risk proﬁle.
5.3. Cardiovascular disease prevention in primary care:
role of the cardiologist
Key message
 The practicing cardiologist should regularly review the
discharge recommendations of the hospital after a cardiac
event or intervention and provide advice in cases where
usual preventive options are difﬁcult to apply.
5.4. Primary care-based self-help programmes
Recommendation on self-help programmes.
Recommendation s Classa Levelb GRADE
Patients with ca rdiac disease 
may pa rticipate in self-help 
programmes to inc rease 
or maintain  awa reness of 
the need for risk factor 
management, for maintaining 
physical fitness , or for diligent 
self-management of oral 
anticoagulation.
IIa B St rong
aClass of recommendation.
bLevel of evidence.5.5. Hospital-based programmes: hospital services
Recommendation on hospital-based programmes.
Recommendation s Classa Levelb GRADE
All patients with 
cardi ovascular disease 
must be discharged f rom 
hospital with clear guideline-
orientated t reatment 
recommendations to 
minimize adverse  events.
I B St rong
aClass of recommendation.
bLevel of evidence.
5.6. Hospital-based programmes: specialized prevention
centres
Recommendation for specialized prevention centres.
Recommendation s Classa Levelb GRADE
All patients requiring 
hospitalization or invasive 
intervention after an acute 
ischaemic event should 
participate in a ca rdiac 
rehabilitation p rogramme 
to imp rove p rognosis  by 
modifying li festyle habits 
and increasing t reatment 
adherenc e.
IIa B St rong
aClass of recommendation.
bLevel of evidence.
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